Nesfatin-1, an 82 amino acid neuropeptide, has recently been characterized as a potent metabolic regulator. However, the metabolic mechanisms and signaling steps directly associated with the action of nesfatin-1 have not been well delineated. We established a loss-of-function model of hypothalamic nesfatin-1/NUCB2 signaling in rats using an adenoviral-mediated RNAi. Using this model, we found that inhibition of central nesfatin-1/NUCB2 activity markedly increased food intake and hepatic glucose flux, and decreased glucose uptake in peripheral tissue in both normal chow diet (NCD)- plays an important role in glucose homeostasis and hepatic insulin sensitivity, which at least in part, is associated with the activation of the mTOR-STAT3 signaling pathway.
INTRODUCTION
The hypothalamus, where numerous neuropeptides and transmitters are released to participate in the control of essential body functions, has been considered to be a key integrator involved in the central control of food intake and energy balance (1, 2).
Nesfatin-1, an 82 amino acid polypeptide, was originally discovered in hypothalamus by Oh et al (3) in the search for new appetite-controlling signals. Nesfatin-1 is the cleavage product of the calcium and DNA-binding protein, nucleobindin2 (NUCB2), a 396 amino acid peptide which is highly conserved in rat, mouse and humans.
NUCB2 mRNA was detected in both brain nuclei, including the arcuate nucleus (ARC), paraventricular (PVN), and supraoptic nucleus (SON), the nucleus of the solitary tract (3) , and in peripheral tissues, such as rat stomach, pancreas, pituitary gland, and testis (4).
Nesfatin-1 was identified as an anorectic molecule. Thus, central injection of nesfatin-1 in rats decreased food intake and body weight in a dose-dependent manner (3) and several other studies have shown that nesfatin-1, when injected into the lateral (5, 6) or the 4 th brain ventricle (5), the PVN (7), or into the abdominal cavity (8) ,
induced a sustained suppression of dark-phase feeding in rodents. Importantly, increasing evidence suggest that nesfatin-1 may also play an import role in the regulation of glucose metabolism as elevated plasma nesfatin-1 concentrations have been found in subjects with impaired glucose tolerance (IGT), with type 2 diabetes mellitus (T2DM) and to be associated with insulin resistance (9) .
Signal transducer and activator of transcription 3 (STAT3), a member of the STAT family of cytoplasmic transcription factors, was found to be activated by
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glycoprotein (gp) 130-coupled cytokines, such as IL-6 (10, 11) . Recent studies have reported that liver-specific STAT3 knockout mice had increased expression of gluconeogenic genes (12) . Further, STAT3 has been found to directly target the regulatory regions of glucose-6-phosphatase (G-6-Pase) and phosphoenolpyruate carboxykinase (PEPCK), and to regulate their expression (11) and has been shown to be involved in the pathogenesis of IL-6-induced insulin resistance in the liver (13) .
We recently reported that hypothalamic nesfatin-1 was involved in the regulation of hepatic glucose production (HGP) via the hepatic AKT kinase/AMPdependent protein kinase/ mammalian target of rapamycin (AKT/AMPK/mTOR) pathway (14) , suggesting a connection between hypothalamic nesfatin-1 and the STAT signaling pathway. To our knowledge, such a connection has not been reported and it has been suggested that it should be confirmed by a loss-of-function study (15) .
In the current study, we have therefore determined whether attenuation of the central nesfatin-1/NUCB2 signal will lead to a change in peripheral glucose metabolism. To this end, we have created a loss-of-function animal model by knocking down the hypothalamic nesfatin-1/NUCB2. This has allowed us to determine molecular mechanisms, by which the central nesfatin-1/NUCB2 knockdown can lead to the alteration in insulin signaling. 7 their familiar housing cages. At the end of the seventh day, rats were anesthetized, and liver samples were freeze-clamped in situ and stored at -80°C for glycogen analysis.
Hyperinsulinemic-euglycemic clamp studies
Twelve hours before the clamp studies, food was removed from every cage. The clamps were performed as previously described (14) . ] glucose-specific activity (dpm/mg). When exogenous glucose was given, the rate of hepatic glucose production (HGP) was calculated as the difference between Ra and glucose infusion rate (GIR) (16) . The rate of 2-DG uptake was calculated as described by Pascal et al (17) with the equation:
The lumped constant (LC), which is a correction factor for the discrimination against 
Nesfatin-1/NUCB2 immunohistochemistry
After being injected with Ad-shNUCB2 or aCSF for 48 hours, the rats were anesthetized by intraperitoneal injection of sodium pentobarbital (1 mg/kg) and perfused first with saline containing heparin (20 U/ml) for 3 min and then with 4% paraformaldehyde in 0.1 M PBS for 20 min. The brains were excised, transferred to 4% paraformaldehyde, and then fixed at 4°C for 24 h. After being dehydrated with (18) .
Western blot analyses
For analysis of nesfatin-1/NUCB2 protein expression in the brain, the hypothalamus was dissected out by a horizontal cut 2 mm in depth with following the limits: 1 mm anteriorly from the optic chiasm, the posterior border of mammillary bodies, and the hypothalamic fissures (19) . Hypothalamus, liver and muscle tissues were 
RESULTS

Molecular approaches to nesfatin-1/NUCB2 inhibition
To inhibit hypothalamic nesfatin-1/NUCB2 signaling, we constructed a shRNA expression vector Ad-shNUCB2 specific to rat nesfatin-1/NUCB2. Three days after injection of Ad-shNUCB2 into the third ventricle, hypothalamic nesfatin-1/NUCB2 protein levels were decreased by 66% (p<0.05) compared with nesfatin-1/NUCB2
protein levels of rats who received aCSF or Ad-shGFP; whereas there was no reductions of nesfatin-1/NUCB2 protein abundance in adipose, liver or muscle tissues (Fig. 1a) .
Effect of intracerebroventricular (ICV) Ad-shNUCB2 injection on nesfatin-1/ NUCB2 expressing neurons
To determine the effect of ICV Ad-shNUCB2 on nesfatin-1/NUCB2 expressing neurons, we performed immunohistochemistry in rat hypothalamic. As shown in Fig 
Effect of hypothalamic nesfatin-1/NUCB2 inhibition on food intake
ICV injection of Ad-shNUCB2 (10 9 PFU/rat) caused a significant increase in food intake in NCD and HFD-fed rats between days 2-7 ( Fig. 2a-c) . Since the greatest increase in food intake induced by ICV Ad-shNUCB2 was on day 3, all subsequent experiments were performed at the third day after ICV Ad-shNUCB2 injection. We
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also examined the change in body weight (BW) on day 7, and no significant differences were found among the rats received Ad-shNUCB2, Ad-shGFP, or aCSF injection (Fig. 2d) . Although HFD-fed rats had significantly decreased hepatic glycogen stores compared with NCD-fed rats (57.04±2.05 vs. 73.36±2.64 mg/g, p<0.01), hypothalamic nesfatin-1/ NUCB2 inhibition failed to change glycogen levels in both NCD-and HFD-fed rats (Fig. 2e) .
Effects of hypothalamic nesfatin-1/NUCB2 inhibition on glucose kinetics
To examine the effect of ICV administration of Ad-shNUCB2 on glucose kinetics, both NCD-and HFD-fed rats received an injection of Ad-shNUCB2, Ad-shGFP, or aCSF 3 days before the hyperinsulinemic-euglycemic clamp studies. After 12 hours of fasting, the plasma insulin, glucose, TC, TG, LDL-C, HDL-C, NEFA levels were similar in NCD-fed rats who had received aCSF, Ad-shNUCB2, or Ad-shGFP injections. However, HFD-fed rats had significantly increased plasma insulin, TC, TG, LDL-C, NEFA, and decreased HDL-C levels compared with NCD-fed rats (p<0.01, Supplemental Table) . During the clamp, NEFA and triglyceride levels were significantly suppressed in all of groups, although they were higher in HFD-fed rats than that in NCD-fed rats (p<0.05, Table 1 ).
GIR, GRd and HGP were determined during the final 30 minutes of the clamp studies when steady state conditions were achieved for plasma glucose and insulin concentrations and GIR. As expected, HFD-feeding decreased GIR (Fig. 3c) , GRd ( Fig. 3d) and suppression of endogenous glucose production by insulin (Fig. 3e) , and increased HGP (Fig. 3f) . Hypothalamic nesfatin-1/NUCB2 inhibition significantly decreased GIR in both NCD-fed (p<0.01) and in HFD-fed groups (p<0.01, Fig. 3c ). In addition, ICV Ad-shNUCB2 administration significantly increased HGP in both NCD-and HFD-fed rats compared with the aCSF controls (p<0.05 or p<0.01, Fig. 3f ), Finally, Ad-shNUCB2 injection significantly decreased insulin induced suppression of endogenous glucose production ( fig. 3e) . Taken together, our data showed that hypothalamic nesfatin-1/NUCB2 knockdown significantly increased peripheral and hepatic insulin resistance.
Effect of hypothalamic nesfatin-1/NUCB2 inhibition on peripheral glucose intake
To further determine whether central nesfatin-1/NUCB2 knockdown decreases insulin-induced peripheral glucose utilization, 2-DG was injected through the intracarotid catheter during the last 45 minutes of the hyperinsulinemic-euglycemic clamp studies (Fig. 4a) . We found that 2-DG utilization rate was significantly decreased in gastrocnemius soleus muscle (Fig. 4b) , white adipose tissue (WAT) (Fig.   4d ), and interscapular brown adipose tissue (BAT) (Fig. 4c) by the central nesfatin-1/NUCB2 knockdown in both NCD and HFD groups. The results indicated that central nesfatin-1/NUCB2 knockdown attenuated peripheral insulin action.
Effect of central nesfatin-1/NUCB2 knockdown on hepatic expression of PEPCK and G-6-Pase
Since central nesfatin-1/NUCB2 knockdown significantly attenuated hepatic insulin action (Fig. 3) , we next examined whether expressions of PEPCK and G-6-Pase, two gluconeogenic enzymes, were altered by this knockdown. HFD feeding for 10 weeks increased hepatic PEPCK and G-6-Pase protein levels (p<0.05). Intriguingly, both (Fig. 6a, b) , IRS-1 (Tyr612) (Fig. 6c,   d ), and Akt (Ser473) (Fig. 6e, f) (p<0.05) were dramatically reduced in liver and muscle tissues of both NCD and HFD rats. These data confirmed that insulin signaling was attenuated in liver and muscle by the central Ad-shNUCB2 knockdown.
Effects of central nesfatin-1/NUCB2 knockdown on the mTOR-STAT3 pathway in the liver
We previously reported that hypothalamic nesfatin-1 is involved in regulation of HGP via hepatic AKT/AMPK/mTOR signaling (14) . mTOR has been shown to activate STAT3 by phosphorylation of Ser727 (10, 20~22). To further characterize signaling mechanism associated with the action of nesfatin-1/ NUCB2, we examined the effects Fig. 7a and b, total STAT3 protein levels were similar in all groups. However, in both NCD-and HFD-fed rats, ICV nesfatin-1/ NUCB2 knockdown induced a dramatic decrease in STAT3 tyrosine phosphorylation in positions 705 (Tyr705) (Fig.   7a) , and serine phosphorylation in position 727 (Ser727) (Fig. 7b) (p<0.05) .
Consistent with our previous reports, 10 weeks HFD inhibited phosphorylation of mTOR (Ser2448) (Fig. 7c) . Furthermore, ICV nesfatin-1/NUCB2 knockdown led to a significant decrease in SOCS3 (Fig. 7d) , a transcriptional target of STAT3.
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DISCUSSION
Nesfatin-1 is a hypothalamic signal peptide involved in feeding behaviors and body weight control (3). Although several lines of evidence have suggested that nesfatin-1 may function as a regulator for energy homeostasis (14) , the mechanisms associated with the action of nesfatin-1 remain to be characterized. In this study, we have established an in vivo hypothalamic nesfatin-1 knockdown model using RNAi of nesfatin-1/NUCB2 expression in the hypothalamus of rats. Using this model, we observed that central nesfatin-1/NUCB2 knockdown did not significantly change the body weight of the mice although food intake was increased about 10% with a maximal effect on day 3. No significant changes in body weight may be related to that treatment time is not long enough (7 days) (3) or the relative small increase in food intake (~ 10%). There are several possiblities for such small effect on food intake: 1) one injection of Ad-shNUCB2 may not be enough for significantly knocking down central nesfatin-1/NUCB2. Because adenovirus-mediated gene expression was considered to be dose and time dependent in a linear fashion (23, 24), multiple injections to increase vector dose may be required for a large effect on gene expression and consequently on the food intake; 2) there was insufficient blockade (50%) of NUCB2 translation at key hypothalamic nuclei related to food intake; and 3) central nesfatin-1 knockdown may lead to an increase of an anoretic hormone, such as leptin (as nesfatin-1 and leptin expression are not parallel) (25). Interestingly, a recent study reported that knockdown of hypothalamic NUCB2 had no effects on food intake or body weight in pubertal female rats (26), suggesting a sex-difference in nesfatin-1 signaling (i.e., a more prominent role in the control of feeding in male rodents).
ICV nesfatin-1/NUCB2 knockdown decreased GIR and glucose uptake in peripheral tissues, and increased HGP during euglycemic-hyperinsulinemia clamp.
These changes were accompanied by a significant increase in the hepatic expression of the enzymes G-6-Pase and PEPCK. In addition, hypothalamic nesfatin-1/NUCB2 knockdown markedly decreased InsR, IRS-1 and Akt phosphorylation in both liver and muscle. As the insulin signaling pathway is generally thought to proceed through receptor-mediated tyrosine phosphorylation of IRS-1, which leads to activation of phosphoinositide 3-kinase (PI3K) and Akt. In blocking gluconeogenesis, insulin reduces transcription of several crucial genes in glucose production, including PEPCK and G-6-Pase (27) . Consistent with our previous report (14) , our results further Interestingly, although SOCS3 was down regulated in liver and total IRS levels were slightly increased (Fig. 6b) , phosphorylation of both IRS and AKT was decreased, which suggested that decreased phosphorylation of IRS and AKT plays a major role in the increased hepatic insulin resistance induced by hypothalamic nesfatin-1/ NUCB2 knockdown.
We have previously reported that hypothalamic nesfatin-1 is involved in regulation of hepatic glucose production via hepatic AKT/AMPK/mTOR signaling (14) . As a member of the phosphatidylinositol kinase-like Ser/Thr kinase family, mTOR appears to activate STAT3 by phosphorylation of Ser727 (10, 20~22). We found that central nesfatin-1/NUCB2 inhibition decreased the activity of mTOR, particularly in HFD-fed rats, leading to decreased phosphorylation of STAT3.
Recently, it has been proposed that over-activation of the mTOR/S6K1 pathway (37, 38) . Ser2448 in mTOR has been identified as a phosphorylation site by AKT in vivo and this phosphorylation depends on PI3K (39) . Therefore, it is likely that hypothalamic nesfatin-1/ NUCB2
knockdown decreased mTOR Ser2448 phosphorylation through inhibition of insulin signaling. Although it is not clear whether these signal transduction changes are direct effects of hypothalamic nesfatin-1 knockdown or indirect effects associated with increased food intake, our previous study demonstrated that central nesfatin-1 infusion could independently and immediately affect hepatic insulin action supporting a direct effect (14) . However, some limitations of this study need to be considered such as lack of a pair-feeding controls, lack of access to insulin levels in the portal vein and an experimental approach to induce a selective inhibition in these signaling pathways. Therefore, further studies are needed to address these issues.
The neural pathways involved in the effects of nesfatin-1/ NUCB 2 on glucose homeostasis remain to be defined. A recent study has reported that nesfatin-1 has either hyperpolarizing or depolarizing effects on most neurons in the PVN (40) . In addition, glucose and insulin may directly activate nesfatin-1 neurons in PVN (41). Our previous study found that ICV nesfatin-1 activated c-fos-positive neurons in the PVN (14) . It is known that the hypothalamus, especially the PVN, via the modulation of the sympathetic parasympathetic balance, takes part in the control of whole body glucose metabolism (42~47). Therefore, it is possible that, like leptin, nesfatin-1/NUCB2 signaling was relayed to the liver, skeletal muscle, or adipocytes contributed to discussion, reviewed/edited manuscript. All the authors gave final approval to the submission of the manuscript.
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